Savara Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, amendments to the certificate of incorporation and incentive plan, auditor ratification, and executive compensation. All proposals passed, and a Q&A session followed for stockholders.
-
MOLBREEVI, an inhaled biologic for autoimmune PAP, is under FDA review with a PDUFA date in November and strong confidence in approval. The US market is estimated at 5,500 patients, with pricing set at $400,000–$500,000 per year and a robust launch plan in place. High retention and safety in trials support broad use, including in mild cases.
-
MOLBREEVI, an inhaled GM-CSF therapy for aPAP, is nearing a key regulatory decision with strong clinical data and significant payer interest. The company is actively expanding diagnosis and awareness, preparing for a U.S. launch, and considering future global opportunities.
-
MOLBREEVI, an inhaled therapy for autoimmune PAP, is under FDA review with strong phase III results and a potential August approval. Commercial launch plans target 5,500 U.S. patients, supported by robust diagnostics, a focused sales force, and a narrowed pricing band of $400,000–$500,000 per year.
-
Molbreevi is under FDA priority review for aPAP, with a PDUFA date set for August 22nd, and parallel filings planned in the EU and UK. The therapy addresses a significant unmet need, targeting all 5,500 diagnosed US patients, and launch preparations include a focused field force and exclusive specialty pharmacy partnership.
-
MOLBREEVI is on track for FDA priority review with a potential August approval, supported by strong phase III data and a robust commercial strategy targeting a concentrated rare disease market. European filings are imminent, and the company is well-funded for independent launches.
-
MOLBREEVI, a novel inhaled biologic for autoimmune PAP, showed strong efficacy and safety in phase III trials and is under FDA review, with US approval targeted for August. The company is scaling diagnostics, commercial infrastructure, and expects robust market access at a $400,000–$500,000 price point.
Fiscal Year 2025
-
Focused on rare lung disease, the company is advancing Molbreevi for autoimmune PAP, with strong Phase 3 data and regulatory filings imminent. The product offers a significant clinical benefit, a favorable safety profile, and is targeting a $400,000–$500,000 annual price point.
-
MOLBREEVI's BLA resubmission is on track for December, with a U.S. launch targeted for next year and European filings planned by Q1. The team is prepared for a robust commercial rollout, supported by strong patient identification efforts, favorable payer feedback, and a solid financial position.
-
Molrivi, an inhaled biologic for autoimmune PAP, is on track for US and EU/UK filings, with a US launch targeted for late next year. Market analysis shows at least 5,500 US patients and strong pricing power, while robust clinical data and early commercial preparations support a confident launch.
-
MOLBREEVI, an inhaled biologic for autoimmune PAP, is set for BLA resubmission in December after resolving FDA manufacturing concerns. Positive IMPALA-2 trial results and expanded US patient estimates support a robust commercial strategy, with a potential launch expected after an August PDUFA date.
-
Mobrevi, an inhaled biologic for autoimmune PAP, showed positive phase 3 results and strong safety, with regulatory submissions planned in the U.S., EU, and UK. Market research and claims data support a sizable commercial opportunity, and financials indicate a cash runway into 2027.
-
Molbrivi, a novel inhaled biologic for aPAP, showed strong efficacy and safety in phase III trials, with regulatory filings planned in the US and EU. Market development efforts and expanded testing have increased diagnosed prevalence, supporting a significant commercial opportunity.
-
MOLBREEVI, a once-daily inhaled therapy for APAP, showed strong phase 3 results and is set for BLA resubmission in Q4, with U.S. and European filings on track. The addressable U.S. market could exceed 7,000 patients, with pricing power and robust commercial planning underway.
-
MOLBREEVI, a novel inhaled therapy for aPAP, showed strong efficacy and safety in phase III trials, with regulatory submissions underway in the U.S. and Europe. Commercial preparations are advancing, supported by robust financials and high stakeholder interest.
-
A novel inhaled biologic for autoimmune PAP is nearing FDA approval, with strong phase III results and a robust commercial strategy targeting both diagnosed and undiagnosed patients. Launch preparations include payer engagement, diagnostic initiatives, and a solid financial runway.
-
MOLBREEVI, a novel inhaled biologic for aPAP, is nearing FDA and EMA submissions following positive phase 3 results. The company is accelerating diagnosis with a new blood test, targeting early adoption among moderate to severe patients, and expects strong reimbursement at a premium price. Long-term data show reduced need for lung lavage and improved patient outcomes.
-
Molbreevi, an inhaled biologic for APAP, is nearing US and EU regulatory filings after positive phase 3 results. The addressable US market is estimated at up to 7,300 patients, with strong physician interest and a robust launch plan. Regulatory exclusivity and proprietary delivery support long-term commercial potential.
-
Molbrevi, a novel inhaled biologic for APAP, is advancing toward regulatory filings in the US and Europe following strong phase 3 results. Patient identification and market development efforts are underway, with a new diagnostic test and international expansion plans supporting future growth.
-
Presenters detailed the significant unmet need in aPAP, highlighted MOLBREEVI's positive Phase III results, and outlined regulatory and commercial plans for US and EU launches. Market expansion is supported by diagnostic innovation and a strong financial position.
Fiscal Year 2024
-
Rolling BLA submission for Molbreevi will begin by end of 2024, with FDA decision expected by late 2025 and EMA filing by year-end 2025. Commercial efforts target 1,000 U.S. patients at launch, with diagnostic and market expansion initiatives underway in both the U.S. and Europe.
-
MOLBREEVI showed strong phase III results for aPAP, with regulatory filings advancing ahead of schedule. The U.S. market targets 3,600 diagnosed patients at a premium price, supported by robust supply chain plans and a $219M cash runway. Diagnostic initiatives aim to expand the patient base.
-
Rolling BLA submission for Molbreevi will start by year-end, with full submission by end of Q1. U.S. and European market strategies target both diagnosed and undiagnosed aPAP patients, leveraging new diagnostic tools and a strong cash position through Q2 2027.
-
Molgramostim demonstrated significant efficacy and safety in a phase III trial for APAP, a rare lung disease with high unmet need. Market potential is strong, with pricing aligned to rare disease standards and a robust commercial and regulatory strategy in place.